Patents by Inventor Hao-Wen Kao

Hao-Wen Kao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RADIOLABELED ACTIVE TARGETING PHARMACEUTICAL COMPOSITION AND THE USE THEREOF
    Publication number: 20180117188
    Abstract: The present invention is related to a radiolabeled active targeting pharmaceutical composition, including: a bioconjugate and a radionuclide, wherein the bioconjugate includes a biomolecule and a metal nanoparticle, wherein the biomolecule has an affinity for receptors on the surface of a cell membrane and is selected from the group consisting of a peptide and a protein. The present invention further provides a method for evaluating a thermal adjuvant therapy for tumors and a kit thereof. The above-mentioned pharmaceutical composition is applied to evaluate a tumor accumulation time, so as to establish the optimal policy for a radiofrequency- or laser-induced thermal adjuvant therapy for tumors.
    Type: Application
    Filed: September 14, 2017
    Publication date: May 3, 2018
    Inventors: Hsin-Ell WANG, Chien-Chung HSIA, Mao-Chi WENG, Kun-Liang LIN, Hao-Wen KAO, Chao-Cheng CHEN, Kwan-Hwa CHI, Der-Chi TIEN, Wuu-Jyh LIN
  • Radiolabeled active targeting pharmaceutical composition and the use thereof
    Patent number: 9789214
    Abstract: The present invention is related to a radiolabeled active targeting pharmaceutical composition, including: a bioconjugate and a radionuclide, wherein the bioconjugate includes a biomolecule and a metal nanoparticle, wherein the biomolecule has an affinity for receptors on the surface of a cell membrane and is selected from the group consisting of a peptide and a protein. The present invention further provides a method for evaluating a thermal adjuvant therapy for tumors and a kit thereof. The above-mentioned pharmaceutical composition is applied to evaluate a tumor accumulation time, so as to establish the optimal policy for a radiofrequency- or laser-induced thermal adjuvant therapy for tumors.
    Type: Grant
    Filed: September 18, 2014
    Date of Patent: October 17, 2017
    Assignees: INSTITUTE OF NUCLEAR ENERGY RESEARCH ATOMIC ENERGY COUNCIL, EXECUTIVE YUAN, NATIONAL YANG-MING UNIVERSITY
    Inventors: Hsin-Ell Wang, Chien-Chung Hsia, Mao-Chi Weng, Kun-Liang Lin, Hao-Wen Kao, Chao-Cheng Chen, Kwan-Hwa Chi, Der-Chi Tien, Wuu-Jyh Lin
  • RADIOLABELED ACTIVE TARGETING PHARMACEUTICAL COMPOSITION AND THE USE THEREOF
    Publication number: 20150231285
    Abstract: The present invention is related to a radiolabeled active targeting pharmaceutical composition, including: a bioconjugate and a radionuclide, wherein the bioconjugate includes a biomolecule and a metal nanoparticle, wherein the biomolecule has an affinity for receptors on the surface of a cell membrane and is selected from the group consisting of a peptide and a protein. The present invention further provides a method for evaluating a thermal adjuvant therapy for tumors and a kit thereof. The above-mentioned pharmaceutical composition is applied to evaluate a tumor accumulation time, so as to establish the optimal policy for a radiofrequency- or laser-induced thermal adjuvant therapy for tumors.
    Type: Application
    Filed: September 18, 2014
    Publication date: August 20, 2015
    Inventors: Hsin-Ell WANG, Chien-Chung HSIA, Mao-Chi WENG, Kun-Liang LIN, Hao-Wen KAO, Chao-Cheng CHEN, Kwan-Hwa CHI, Der-Chi TIEN, Wuu-Jyh LIN
  • 18F-labeled monomeric galactose derivative used as tomography probe
    Patent number: 8961931
    Abstract: A 18F-labeled monomeric galactose derivative is provided as a tomography probe. The derivative is a positron emission tomography (PET) probe. The derivative has high affinity and good stability in animal's body. The derivative can be an alternative glucose metabolism imaging agent used in clinic examination and quantification.
    Type: Grant
    Filed: April 7, 2011
    Date of Patent: February 24, 2015
    Assignee: Institute of Nuclear Energy Research, Atomic Energy Council
    Inventors: Ting-Shien Duh, Wuu-Jyh Lin, Jenn-Tzong Chen, Li-Yuan Huang, Hsin-Ell Wang, Chuan-Lin Chen, Wen-Yi Chang, Hao-Wen Kao
  • 18F-Labeled Monomeric Galactose Derivative Used as Tomography Probe
    Publication number: 20120259102
    Abstract: A 18F-labeled monomeric galactose derivative is provided as a tomography probe. The derivative is a positron emission tomography (PET) probe. The derivative has high affinity and good stability in animal's body. The derivative can be an alternative glucose metabolism imaging agent used in clinic examination and quantification.
    Type: Application
    Filed: April 7, 2011
    Publication date: October 11, 2012
    Applicant: ATOMIC ENERGY COUNCIL-INSTITUTE OF NUCLEAR ENERGY RESEARCH
    Inventors: Ting-Shien Duh, Wuu-Jyh Lin, Jenn-Tzong Chen, Li-Yuan Huang, Hsin-Ell Wang, Chuan-Lin Chen, Wen-Yi Chang, Hao-Wen Kao